Clinical trials: IBD (Inflammatory Bowel Disease)
- Condition IBD (Inflammatory Bowel Disease)
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Inflammatory Bowel Disease(IBD)
Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults Volunteers
This is a randomized, double-blind, placebo-controlled, ascending dose study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part (Part B).
- Trial name
- NCT07911982
- Testing
- ICP-B161 (SC or IV)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Inflammatory Bowel Disease (IBD)
A Phase 1 Study of PVT401 in Healthy Subjects
The goal of this clinical trial is to learn what happens to PVT401 when it enters the human body and how it affects the immune system.
- Trial name
- NCT07423000
- Testing
- PVT401, Normal Saline (0.9% NaCl)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Parvus Therapeutics, Inc.
Inflammatory Bowel Disease (IBD)
Phase I Study of QLS1510 Tablets in Healthy Participants
This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QLS1510 in Healthy participants
- Trial name
- NCT07760077
- Testing
- QLS1510 Tablets
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Ulcerative Colitis (UC), Ulcerative Colitis (Disorder)
A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult
A Phase 1, 2-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of BDHK-2009 (Part 1) and multiple oral doses (Part 2) of BDHK-200 in…
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis (Disorder), Ulcerative Colitis Acute, IBD (Inflammatory Bowel Disease)
- Trial name
- NCT07632573
- Testing
- BDHK-2009 Tablets
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Benethera (Shaoxing) Biotechnology Co., Ltd.
IBD (Inflammatory Bowel Disease)
A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)
A Phase Ⅰ, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Voluteers.
- Trial name
- INT-210-I101 (NCT07616791)
- Testing
- INT-210 Capsule
- Where
- China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Innatus Therapeutics (Shanghai) Co., Ltd.
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
This study is evaluating the levels of calprotectin, a protein found in stool, in healthy adults. Calprotectin is a marker of inflammation in the intestines and can help doctors tell the difference between inflammatory bowel…
- Conditions
- IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
- Trial name
- NCT07089420
- Testing
- ALPCO Calprotectin CLIA
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome)
Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.
This study will evaluate how well the a new stool test can distinguish inflammatory bowel disease (IBD) from non-IBD conditions compared with standard calprotectin testing and colonoscopy findings.
- Conditions
- IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome), Gastrointestinal Symptoms
- Trial name
- COMBI (NCT07471490)
- Where
- 2 sites in United States, Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- DiaSorin Inc.
Healthy Participants, IBD (Inflammatory Bowel Disease)
A Phase I Study of HW201877 in Healthy Subjects
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single…
- Trial name
- NCT07373457
- Testing
- HW201877 capsules
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Inflammatory Bowel Diseases, IBD
Multiple Dose Ethnobridging PK Study in Healthy Subjects
A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
- Trial name
- NCT03750565
- Testing
- TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma